GlassScriptPhysician profile
Rashmi Nanda
NPI 1043273097
$1,797.48
in general payments reported to CMS, 2019-2025
26 companies · $89.62 in 2025
The $89.62 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $291 · 2021: $389 · 2022: $245 · 2023: $105 · 2024: $200 · 2025: $89.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $391.34 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $223.73 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $169.05 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $127.50 | 2024 | |
| Allergan, INC. | $126.99 | 2019-2020 | |
| Abbott Laboratories | $88.16 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $73.47 | 2019-2025 | |
| Abbvie INC. | $70.53 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.78 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.36 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $51.65 | 2019-2020 | |
| Genzyme Corporation | $44.82 | 2022-2023 | |
| Amarin Pharma, INC. | $41.75 | 2019-2021 | |
| Astellas Pharma US INC | $41.14 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $31.19 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $28.73 | 2021 | |
| Insmed, INC. | $27.80 | 2025 | Arikayce |
| Glaxosmithkline, LLC. | $24.17 | 2019 | |
| Mylan Specialty L.P. | $23.23 | 2019 | |
| Exact Sciences Corporation | $20.40 | 2025 | Cologuard Collection Kit |
| Edwards Lifesciences Corporation | $15.99 | 2020 | |
| Amgen INC. | $14.95 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.42 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.06 | 2019 | |
| Ascend Therapeutics US, LLC | $12.45 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashmi Nanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.